Magnetar Financial’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Magnetar Financial’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,085	Closed	-$386K	–	911
2020 Q3	$386K	Buy	+9,085	New	+$397K	0.01%	486
2019 Q4	–	Sell	-15,173	Closed	-$858K	–	664
2019 Q3	$858K	Sell	15,173 -339	-2%	-$19.1K	0.02%	269
2019 Q2	$864K	Buy	15,512 +560	+4%	+$29.2K	0.02%	216
2019 Q1	$755K	Buy	+14,952	New	+$665K	0.02%	197
2018 Q4	–	Sell	-4,068	Closed	-$282K	–	525
2018 Q3	$282K	Buy	4,068 +761	+23%	+$57.7K	0.01%	351
2018 Q2	$250K	Sell	3,307 -1,235	-27%	-$77.7K	﹤0.01%	427
2018 Q1	$239K	Buy	4,542 +332	+8%	+$19.3K	﹤0.01%	501
2017 Q4	$225K	Buy	+4,210	New	+$234K	﹤0.01%	589
2017 Q3	–	Sell	-8,258	Closed	-$651K	–	948
2017 Q2	$651K	Buy	8,258 +2,029	+33%	+$166K	0.01%	455
2017 Q1	$517K	Buy	+6,229	New	+$463K	0.01%	467

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Magnetar Financial's EGRX Position: Q4 2020 in Review

Magnetar Financial sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2020, closing a stake of 9,085 shares — an estimated $386K sold.

Magnetar Financial first reported a position in EGRX in Q1 2017 and held it in 10 quarters. The position peaked at $864K in Q2 2019. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

Magnetar Financial reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Magnetar Financial sold 9,085 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $386K.
Magnetar Financial first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and held it in 10 quarters.
Magnetar Financial's Eagle Pharmaceuticals, Inc. position peaked at $864K in Q2 2019.
166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Magnetar Financial's 13F filing for Q4 2020, filed 12 Feb 2021.